Page 999«..1020..9989991,0001,001..1,0101,020..»

Knowing Signs and Symptoms of Lyme Disease Is Critical for Early Detection and Treatment, Says Industry-Leading Quidel – Business Wire

Posted: June 3, 2020 at 6:43 pm

SAN DIEGO--(BUSINESS WIRE)--With America on lockdown the past two months, many people turned to the woods for safe isolation and social distancing. And now as sections of the country reopen and summer approaches, the outdoors will be filled with hikers, campers, hunters and fishermen. It will also be filled with ticks that may be carrying the bacterial infection that spreads Lyme disease to humans and pets.

Unlike a mosquito bite where people know immediately if they have been bitten, a tick bite may go undetected; and one of the challenges with Lyme disease is that symptoms may not appear for two to six weeks. That makes it critically important to take steps to avoid catching the disease and to know its warning signs so treatment can begin early when it is most effective.

While not all deer ticks cause Lyme disease, it is still smart to avoid areas where deer ticks live, especially wooded, bushy areas with long grass, said Sean McCloy, M.D., a family medicine physician with an expertise in Lyme disease at the Integrative Health Center of Maine. You can decrease your risk of getting Lyme disease with some simple precautions, such as wearing shoes, long pants tucked into your socks, a long-sleeved shirt, a hat and gloves. And after spending time in vulnerable areas you should always check your clothing, yourself, your children and your pets for ticks; and remove any that you find as soon as possible with tweezers. Only a minority of tick bites leads to Lyme disease; but the longer the tick remains attached to your skin, the greater your risk of getting the disease.

For those who are bitten by an infected tick, early warning signs include fever, headache, fatigue, joint pain, swollen lymph nodes, weakness in the limbs and a characteristic skin rash often in a bull's-eye pattern. If untreated, new symptoms could include neurological problems and, though less common, heart problems (such as an irregular heartbeat), eye inflammation, liver inflammation and severe fatigue.

If you think you've been bitten and have signs and symptoms of Lyme diseaseparticularly if you live in an area where Lyme disease is prevalentit is critical to get tested as treatment is more effective if begun early, said Robert Dracker, M.D., chairman of the heart, lung and cancer committee for the Medical Society of New York and medical director of Summerwood Pediatrics and Infusacare Medical Services in New York. Fortunately, new tests are available that are easy to administer and provide results faster than ever.

Leading the way in Lyme disease testing is the innovative Sofia 2 Lyme FIA test. This in-office test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctors office or local clinic, it is also the only test that can get results from a simple finger prick of blood. The test was developed by Quidel, a California-based diagnostic healthcare manufacturer and one of the nations leaders in developing rapid diagnostic health solutions.

Given that the vast majority of patients tested are negative, getting results quickly will mean discernable peace of mind and remove a significant weight off a persons shoulders, said Dr. Dracker. Not having to wait days for test results allows physicians and nurse practitioners to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative.

Patients seeking more information are encouraged to contact their private physician to find out more about the availability of this innovative new test in their area. More information on Quidel may be obtained at quidel.com.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Quidels products aid in the detection and diagnosis of many critical diseases and conditions including not only Lyme disease but, among others, influenza, respiratory syncytial virus, strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidels research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians offices and hospital and reference laboratories. For more information about Quidel, visit quidel.com.

Excerpt from:
Knowing Signs and Symptoms of Lyme Disease Is Critical for Early Detection and Treatment, Says Industry-Leading Quidel - Business Wire

Posted in Integrative Medicine | Comments Off on Knowing Signs and Symptoms of Lyme Disease Is Critical for Early Detection and Treatment, Says Industry-Leading Quidel – Business Wire

iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19 | 2020-06-01 | Press Releases – Stockhouse

Posted: June 3, 2020 at 6:43 pm

NASHUA, N.H., June 01, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm PT. Event registration is available via this link: https://register.gotowebinar.com/register/5960832272590383888.

The roundtable will feature leading specialists in breast cancer treatment, including the following experts*:

The COVID-19 pandemic has introduced unprecedented challenges to our health care system and specifically impacted cancer screenings and treatment in our country and worldwide. During these extraordinary times, it is imperative for clinicians to share best practices and adapt approaches to patient care. iCAD is honored to host virtual events such as this, which provide an educational forum for clinicians to enhance patient care during this global healthcare crisis and beyond,” according to Stacey Stevens, President of iCAD. In the face of this pandemic, iCAD’s technology is now more relevant than ever. Intraoperative radiation therapy (IORT) with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® offers a viable solution that could potentially alleviate the burden to our health system, while enabling clinicians to administer high-quality care to patients who are candidates, while minimizing their potential exposure to the novel coronavirus.”

Xoft breast IORT is a single-fraction therapy option that allows select early-stage breast cancer patients to replace weeks of daily radiation with one treatment, delivered at the time of surgery. This targeted treatment option offers a full course of radiation in just one day, which could contribute to a reduction in the healthcare system resources needed for breast cancer patients during the COVID-19 pandemic and reduce those patients’ risk of exposure to the novel coronavirus by minimizing the number of visits required to a hospital or medical facility.

In the recent months during the COVID-19 pandemic, hospital resources have become limited in many areas, and guidelines issued by a number of medical societies advise clinicians to determine how best to triage the care of cancer patients safely.1 Some breast cancer patients are choosing to delay parts of their treatment for safety concerns,” according to Sadia Khan, DO, FACS, Assistant Clinical Professor of Surgery at Keck School of Medicine, USC, Director of Integrative Breast Oncology at Hoag Breast Program. In areas where there is still a high incidence of COVID-19, some patients with breast cancer may opt to choose IORT, which offers a one-dose radiation option for patients who meet the criteria. For those who are candidates, IORT gives patients an additional option to complete their radiation in a one-time dose, which decreases their exposure to the hospital.”

Positive results from a long-term study involving Xoft breast IORT conducted at Hoag Memorial Hospital Presbyterian were published in the Annals of Surgical Oncology in 2019.2 Led by Melvin J. Silverstein, MD, Medical Director of the Hoag Breast Center, the prospective study, titled Intraoperative Radiation Therapy (IORT): A Series of 1000 Tumors, found breast cancer recurrence rates of patients who were treated with Xoft breast IORT were comparable to those seen in the cornerstone, randomized TARGIT-A and ELIOT trials, which evaluated IORT using different technology.

A number of breast cancer patients at our facility have had their treatment delayed due to the COVID-19 pandemic. This is concerning to physicians and patients alike, as some cases could potentially progress and it could result in a considerable backlog of patients who require urgent treatment with more advanced disease,” according to Michael Howard, PhD, DABMP, RSO, Director of Oncology Services, Chief of Medical Physics, Sarah Cannon Cancer Institute, Parkridge Medical Center, HCA Healthcare. The concern for a second wave of COVID is very real, but IORT offers a way to help reduce this potential backlog.”

The reality is, IORT may be able to play a bigger role right now in the treatment of patients. In some cases, it may be ultimately more beneficial to offer IORT to avoid the backlog in treatment as a means of not overrunning hospitals and radiation centers once we are back up and running,” added Barry Rosen, MD, FACS, Chief of Breast Surgery, Advocate Healthcare and Managing Partner, TME. IORT is one of those exceptional interventions that I believe satisfies the triple aim in treatment: it offers benefits to patients, providers and payers alike. For patients, it offers added convenience, with better cosmetic outcomes and fewer side effects; from a physician standpoint there is an inherent efficiency, as it enables them to condense one month of daily treatments to a single dose of targeted radiation. Lastly, for payers, the overall cost of treatment is reduced as the course of treatment may be reduced from weeks of daily fractions to one concentrated dose of radiation, administered at the time of surgery.”

As clinicians, we are going to have to adapt to the COVID-19 situation as it evolves. At a certain point, delaying treatment for even early-stage breast cancer is going to come with risk. In many cases, the decision really should be made to go forward with cancer treatment; IORT offers a treatment option that may allow more women to get the treatment they need during this time,” according to Charles Wesley Hodge, MD, Radiation Oncologist, Florida Hospital Celebration Health/AdventHealth. We are facing an unprecedented challenge in healthcare, and as clinicians we need to come together and adjust to these new realities. For those of us who practice in the oncology space, it is particularly challenging because we are dealing with a potentially life-threatening illness that requires appropriate management. Now is the time for clinicians to work together, to adjust to our new reality, and to come up with an approach that will do the greatest good for our patients.”

This virtual roundtable event is a part of larger series of webinars hosted by iCAD in recent weeks, featuring leading experts in breast cancer detection and treatment. This series has examined various aspects of breast cancer care in the era of COVID-19, including risk adaptive tools and pragmatic solutions for both screening and treatment. To view the schedule, register for an upcoming free event, or view a prior event on-demand, visit https://www.icadmed.com/educational-webinars.html.

*Panelists have been compensated with an honoraria/speaking fee, but are encouraged to provide their own expert opinions and viewpoints. Dr. Patel is a member of iCAD’s Board of Directors.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

ProFound AI is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.1

The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.

For more information, visit http://www.icadmed.com and http://www.xoftinc.com.

Forward-Looking Statements

Certain statements contained in this News Release constitute forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the ability of IORT to alleviate the burden to our health system and minimize a patient’s potential exposure to Covid-19, to be more beneficial for patients that traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words believe,” demonstrate,” intend,” expect,” estimate,” will,” continue,” anticipate,” likely,” seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contacts: Media inquiries: Jessica Burns, iCAD +1-201-423-4492 jburns@icadmed.com

Investor Relations: Jeremy Feffer, LifeSci Advisors +1-212-915-2568 jeremy@lifesciadvisors.com

See the original post:
iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19 | 2020-06-01 | Press Releases - Stockhouse

Posted in Integrative Medicine | Comments Off on iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19 | 2020-06-01 | Press Releases – Stockhouse

Princeton team develops ‘poisoned arrow’ to defeat antibiotic-resistant bacteria – Princeton University

Posted: June 3, 2020 at 6:43 pm

Poison is lethal all on its own as are arrows but their combination is greater than the sum of their parts. A weapon that simultaneously attacks from within and without can take down even the strongest opponents, from E. coli to MRSA (methicillin resistant Staphylococcus aureus).

A team of Princeton researchers reported today in the journal Cell that they have found a compound, SCH-79797, that can simultaneously puncture bacterial walls and destroy folate within their cells while being immune to antibiotic resistance.

Bacterial infections come in two flavors Gram-positive and Gram-negative named for the scientist who discovered how to distinguish them. The key difference is that Gram-negative bacteria are armored with an outer layer that shrugs off most antibiotics. In fact, no new classes of Gram-negative-killing drugs have come to market in nearly 30 years.

This is the first antibiotic that can target Gram-positives and Gram-negatives without resistance, said Zemer Gitai, Princetons Edwin Grant Conklin Professor of Biology and the senior author on the paper. From a Why its useful perspective, thats the crux. But what were most excited about as scientists is something weve discovered about how this antibiotic works attacking via two different mechanisms within one molecule that we are hoping is generalizable, leading to better antibiotics and new types of antibiotics in the future.

Gitai poses with James Martin, who led the research team and is first author on the new article about the poisoned arrow antibiotic, at Martins 2019 Ph.D. thesis defense.

The greatest weakness of antibiotics is that bacteria evolve quickly to resist them, but the Princeton team found that even with extraordinary effort, they were unable to generate any resistance to this compound. This is really promising, which is why we call the compounds derivatives Irresistin, Gitai said.

Its the holy grail of antibiotics research: an antibiotic that is effective against diseases and immune to resistance while being safe in humans (unlike rubbing alcohol or bleach, which are irresistibly fatal to human cells and bacterial cells alike).

For an antibiotics researcher, this is like discovering the formula to convert lead to gold, or riding a unicorn something everyone wants but no one really believes exists, said James Martin, a 2019 Ph.D. graduate who spent most of his graduate career working on this compound. My first challenge was convincing the lab that it was true, he said.

But irresistibility is a double-edged sword. Typical antibiotics research involves finding a molecule that can kill bacteria, breeding multiple generations until the bacteria evolve resistance to it, looking at how exactly that resistance operates, and using that to reverse-engineer how the molecule works in the first place.

But since SCH-79797 is irresistible, the researchers had nothing to reverse engineer from.

This was a real technical feat, said Gitai. No resistance is a plus from the usage side, but a challenge from the scientific side.

The research team had two huge technical challenges: Trying to prove the negative that nothing can resist SCH-79797 and then figuring out how the compound works.

To prove its resistance to resistance, Martin tried endless different assays and methods, none of which revealed a particle of resistance to the SCH compound. Finally, he tried brute force: for 25 days, he serially passaged it, meaning that he exposed bacteria to the drug over and over and over again. Since bacteria take about 20 minutes per generation, the germs had millions of chances to evolve resistance but they didnt. To check their methods, the team also serially passaged other antibiotics (novobiocin, trimethoprim, nisin and gentamicin) and quickly bred resistance to them.

Proving a negative is technically impossible, so the researchers use phrases like undetectably-low resistance frequencies and no detectable resistance, but the upshot is that SCH-79797 is irresistible hence the name they gave to its derivative compounds, Irresistin.

They also tried using it against bacterial species that are known for their antibiotic resistance, including Neisseria gonorrhoeae, which is on the top 5 list of urgent threats published by the Center for Disease Control and Prevention.

Gonorrhea poses a huge problem with respect to multidrug resistance, said Gitai. Weve run out of drugs for gonorrhea. With most common infections, the old-school generic drugs still work. When I got strep throat two years ago, I was given penicillin-G the penicillin discovered in 1928! But for N. gonorrhoeae, the standard strains that are circulating on college campuses are super drug resistant. What used to be the last line of defense, the break-glass-in-case-of-emergency drug for Neisseria, is now the front-line standard of care, and there really is no break-glass backup anymore. Thats why this one is a particularly important and exciting one that we could cure.

The researchers even got a sample of the most resistant strain of N. gonorrhoeae from the vaults of the World Health Organization a strain that is resistant to every known antibiotic and Joe showed that our guy still killed this strain, Gitai said, referring to Joseph Sheehan, a co-first-author on the paper and the lab manager for the Gitai Lab. Were pretty excited about that.

Without resistance to reverse engineer from, the researchers spent years trying to determine how the molecule kills bacteria, using a huge array of approaches, from classical techniques that have been around since the discovery of penicillin through to cutting-edge technology.

Martin called it the everything but the kitchen sink approach, and it eventually revealed that SCH-79797 uses two distinct mechanisms within one molecule, like an arrow coated in poison.

Princeton authors on the paper include Joseph Sheehan (left), Gabriel Moore (fourth from left, in blue), Sophia Hsin-Jung Li (fifth from left, in pink), James Martin (fourth from right, in baseball cap), Zemer Gitai (second from right), and Benjamin Bratton (right), seen here on a pre-social-distancing walk across the Princeton campus.

Photo courtesy of the researchers

The arrow has to be sharp to get the poison in, but the poison has to kill on its own, too, said Benjamin Bratton, an associate research scholar in molecular biology and a lecturer in the Lewis Sigler Institute for Integrative Genomics, who is the other co-first-author.

The arrow targets the outer membrane piercing through even the thick armor of Gram-negative bacteria while the poison shreds folate, a fundamental building block of RNA and DNA. The researchers were surprised to discover that the two mechanisms operate synergistically, combining into more than a sum of their parts.

If you just take those two halves there are commercially available drugs that can attack either of those two pathways and you just dump them into the same pot, that doesnt kill as effectively as our molecule, which has them joined together on the same body, Bratton said.

There was one problem: The original SCH-79797 killed human cells and bacterial cells at roughly similar levels, meaning that as a medicine, it ran the risk of killing the patient before it killed the infection. The derivative Irresistin-16 fixed that. It is nearly 1,000 times more potent against bacteria than human cells, making it a promising antibiotic. As a final confirmation, the researchers demonstrated that they could use Irresistin-16 to cure mice infected with N. gonorrhoeae.

This poisoned arrow paradigm could revolutionize antibiotic development, said KC Huang, a professor of bioengineering and of microbiology and immunology at Stanford University who was not involved in this research.

The thing that cant be overstated is that antibiotic research has stalled over a period of many decades, Huang said. Its rare to find a scientific field which is so well studied and yet so in need of a jolt of new energy.

The poisoned arrow, the synergy between two mechanisms of attacking bacteria, can provide exactly that, said Huang, who was a postdoctoral researcher at Princeton from 2004 to 2008. This compound is already so useful by itself, but also, people can start designing new compounds that are inspired by this. Thats what has made this work so exciting.

In particular, each of the two mechanisms the arrow and the poison target processes that are present in both bacteria and in mammalian cells. Folate is vital to mammals (which is why pregnant women are told to take folic acid), and of course both bacteria and mammalian cells have membranes. This gives us a lot of hope, because theres a whole class of targets that people have largely neglected because they thought, Oh, I cant target that, because then I would just kill the human as well, Gitai said.

A study like this says that we can go back and revisit what we thought were the limitations on our development of new antibiotics, Huang said. From a societal point of view, its fantastic to have new hope for the future.

Other Princetonians involved in the research include molecular biology graduate student Gabriel Moore; then-graduate students Maxwell Wilson and Sophia Hsin-Jung Li, who completed their Ph.D. degrees in 2015 and 2018 respectively; Hahn Kim, the director of the Small Molecule Screening Center in Princetons Department of Chemistry; and Joshua Rabinowitz, a professor of chemistry and the Lewis-Sigler Institute for Integrative Genomics.

A dual-mechanism antibiotic kills Gram-negative bacteria and avoids drug resistance, by James K. Martin, Joseph P. Sheehan, Benjamin P. Bratton, Gabriel M. Moore, Andre Mateus, Sophia Hsin-Jung Li, Hahn Kim, Joshua D. Rabinowitz, Athanasios Typas, Mikhail M. Savitski, Maxwell Z. Wilson, and Zemer Gitai, appears in the June 25 issue of the journal Cell and was released online on June 3 (DOI: 10.1016/j.cell.2020.05.005). The research was supported primarily by the National Institutes of Health (DP1AI124669 to ZG, JPS, BPB, JKM) with additional funding from the National Science Foundation (NSF PHY-1734030). Flow cytometry was performed at the Princeton University Flow Cytometry Resource Facility, supported by the National Cancer Institute (NCI-CCSG P30CA072720-5921).

Go here to see the original:
Princeton team develops 'poisoned arrow' to defeat antibiotic-resistant bacteria - Princeton University

Posted in Integrative Medicine | Comments Off on Princeton team develops ‘poisoned arrow’ to defeat antibiotic-resistant bacteria – Princeton University

Quick and Cheap: RT-Lamp COVID-19 tests to cost up to Rs 200, give results in less than an hour, says CSIR – Times Now

Posted: June 3, 2020 at 6:43 pm

Quick and Cheap: RT-Lamp COVID-19 tests to cost up to Rs 200, give results in less than an hour, says CSIR  |  Photo Credit: iStock Images

New Delhi [India], May 27 (ANI): The Council for Scientific and Industrial Research (CSIR) has signed an MoU with Reliance to develop a new RT-LAMP COVID-19 diagnostic kit, which is cheap and gives a quick result, said Director-General Dr Shekhar C Mande on Wednesday.

COVID-19 RT-LAMP (Reverse Transcriptase-Loop Mediated Isothermal Amplification) test is a nucleic acid-based test carried out from nasal or throat swab samples from the patients. The test has been developed and successfully demonstrated using synthetic templates.

Talking about the test, Dr Mande said that "RT-LAMP test is cheap because you don't need to have instrument cost. It's also quite quick. You can actually take it into different areas. You can very quickly take it into the rural area."

The CSIR on Tuesday had announced that the Institute of Integrative Medicine in Jammu has tied up with Reliance Industries Ltd to develop and scale-up a new RT-LAMP based COVID-19 diagnostic kit.

Dr Mande said that the new testing kit "could cost between Rs 100 and Rs 200. It will take less than an hour for a test to do. Within one hour, we can get the result."

Talking about the difference between Feluda test and RT-LAMP kit, Dr Mande said: "Technological basis of Feluda kit and RT-LAMP kit is different. Faluda is based on technique call crisper cash, while RT-LAMP is based on RT-PCR. There is isothermal PCR. So, the technology of both kits is different."

"RT PCR requires a specialised machine. The first step is a reverse transcription that is common to both RT-PCR as well as RT-LAMP. The second step is once DNA is made from RNA, the PCR quantitative to PCR machine does three cycles of temperature," added he.

The CSIR-DG said further said: "In this condition, you do something at 92 degrees; you do something at 55 degrees; you do something at 73 degrees, and you keep cycling between these three temperatures about 25 and 30 times, and in each cycle the number of DNA molecules doubles and you measure. That is in the fluorescent level. So that is a base of RT-PCR."

"But RT-PCR required this machine the fluorescent level is costly and it takes time. On the other hand, the RT-LAMP test is using only four to six primers for the amplification of DNA. It uses four and six primers and you do the amplification of DNA. First of all, it is common for converting RNA into DNA. When in the second step, you use only a single temperature something like 60-degree Celsius," he added.

Dr Mande informed that the Institute of Integrative Medicine in Jammu and Reliance Industries Ltd have agreed that they will scale up the production of the test kit.

Originally posted here:
Quick and Cheap: RT-Lamp COVID-19 tests to cost up to Rs 200, give results in less than an hour, says CSIR - Times Now

Posted in Integrative Medicine | Comments Off on Quick and Cheap: RT-Lamp COVID-19 tests to cost up to Rs 200, give results in less than an hour, says CSIR – Times Now

Hesperos Human-on-a-Chip used to model Alzheimer’s and MCI – SelectScience

Posted: June 2, 2020 at 9:45 pm

Hesperos haveannounced a new peer-reviewed publication that describes how the companys functional Human-on-a-Chip system can be used as a drug discovery platform to identify therapeutic interventions targeting the preclinical stages of Alzheimers disease (AD) and mild cognitive impairment (MCI). The manuscript, titled A human induced pluripotent stem cell-derived cortical neuron human-on-a-chip system to study A42 and tau-induced pathophysiological effects on long-term potentiation, was published this week in Alzheimer's & Dementia: Translational Research & Clinical Interventions. The work was conducted in collaboration with the University of Central Florida and with David G. Morgan, Ph.D., Professor of Translational Neuroscience at Michigan State University, and expert in AD pathology.

To date, more than 100 potential therapeutics in development for AD have been abandoned or failed during clinical trials. These therapeutics relied on research conducted in preclinical animal studies, which often are unable to accurately capture the full spectrum of the human disease phenotype, including differences in drug metabolism and excretion between humans and animals. Therefore, there is a need for human models, especially those that accurately recapitulate the functional impairments during the preclinical phases of AD and MCI.

Hesperos offers a breakthrough technology that provides a human cell-based assay based on cognitive function metrics to evaluate drugs designed to restore cognition at early stages of the Alzheimers continuum, said Dr. Morgan. This system can serve as a novel drug discovery platform to identify compounds that rescue or alleviate the initial neuronal deficits caused by A1-42 and/or tau oligomers, which is a main focus of clinical trials.

In 2018, Hesperos received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) division within the US National Institutes of Health (NIH) to help create a new multi-organ human-on-a-chip model for testing AD drugs. Research conducted under this grant included a study to assess therapeutic interventions based on functional changes in neurons, not neuronal death.

In the recent Alzheimer's & Dementia publication, Hesperos describes its in vitro human induced pluripotent stem cell (iPSC)-derived cortical neuron human-on-a-chip system for the evaluation of neuron morphology and function after exposure to toxic A and tau oligomers as well as brain extracts from AD transgenic mouse models.

Researchers are now focusing on biomarker development and therapeutic intervention before symptoms arise in AD and MCI, said James Hickman, Ph.D., Chief Scientist at Hesperos and Professor at the University of Central Florida. By studying functional disruption without extensive cell loss, we now have a screening methodology for drugs that could potentially evaluate therapeutic efficacy even before the neurodegeneration in MCI and AD occurs.

The researchers found that compared to controls, treatment with toxic A and tau oligomers or brain extracts on the iPSC cortical neurons significantly impaired information processing as demonstrated by reduction in high-frequency stimulation-induced long-term potentiation (LTP), a process that is thought to underlie memory formation and learning. Additionally, oligomer and brain extract exposure led to dysfunction in iPSC cortical neuron electrophysiological activity, including decreases in ion current and action potential firing.

While exposure to the toxic oligomers and brain extracts caused morphological defects in the iPSC cortical neurons, there was no significant loss in cell viability.

Clinical success for AD therapies has been challenging since preclinical animal studies often do not translate to humans, said Michael L. Shuler, Ph.D., Chief Executive Officer of Hesperos. With our recent study, we are now one step closer in developing an AD multi-organ model to better evaluate drug metabolism in the liver, penetration through the blood-brain barrier and the effects on neuronal cells.

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

Read the original:
Hesperos Human-on-a-Chip used to model Alzheimer's and MCI - SelectScience

Posted in Michigan Stem Cells | Comments Off on Hesperos Human-on-a-Chip used to model Alzheimer’s and MCI – SelectScience

Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts – Texas A&M University Today

Posted: June 2, 2020 at 9:44 pm

NICE ink developed by Texas A&M researchers can be used to 3D print customizable craniofacial implants.

Courtesy of Akhilesh Gaharwar

Subtle variations in the architecture of the 22 bones of the skull give each one of us a unique facial profile. So repairing the shape of skull defects, in the event of a fracture or a congenital deformity, calls for a technique that can be tailored to an individuals face or head structure.

In a new study, researchers at Texas A&M University have combined 3D printing, biomaterial engineering and stem cell biology to create superior, personalized bone grafts. When implanted at the site of repair, the researchers said these grafts will not only facilitate bone cells to regrow vigorously, but also serve as a sturdy platform for bone regeneration in a desired, custom shape.

Materials used for craniofacial bone implants are either biologically inactive and extremely hard, like titanium, or biologically active and too soft, like biopolymers, said Roland Kaunas, associate professor in the Department of Biomedical Engineering. In our study, we have developed a synthetic polymer that is both bioactive and mechanically strong. These materials are also 3D printable, allowing custom-shaped craniofacial implants to be made that are both aesthetically pleasing and functional.

A detailed report on the findings was published online in the journalAdvanced Healthcare Materialsin March.

Each year, about 200,000 injuries occur to bones of the jaw, face and head. For repair, physicians often hold these broken bones in place using titanium plates and screws so that surrounding bone cells can grow and form a cover around the metal implant. Despite its overall success in aiding bone repair, one of the major drawbacks of titanium is that it does not always integrate into bone tissue, which can then cause the implant to fail, requiring another surgery in advanced cases.

Thus, biocompatible polymers, particularly a type called hydrogels, offer a preferable alternative to metal implants. These squishy materials can be loaded with bone stems cells and then 3D printed to any desired shape. Also, unlike titanium plates, the body can degrade hydrogels over time. However, hydrogels also have a known weakness.

Although the pliability of hydrogel-based materials makes them good inks for 3D bioprinting, their softness compromises the mechanical integrity of the implant and the accuracy of printed parts, said Akhilesh Gaharwar, associate professor in the Department of Biomedical Engineering.

To increase the stiffness of the hydrogel, the researchers developed a nanoengineered ionic-covalent entanglement or NICE recipe containing just three main ingredients: an extract from seaweed called kappa carrageenan, gelatin and nanosilicate particles that both stimulate bone growth and mechanically reinforce the NICE hydrogel.

First, they uniformly mixed the gelatin and kappa carrageenan at microscopic scales and then added the nanosilicates. Gaharwar said the chemical bonds between these three items created a much stiffer hydrogel for 3D bioprinting with an almost eight-fold increase in strength compared to individual components of NICE bioink.

Next, they added adult stem cells to 3D parts printed with NICE ink and then chemically induced the stem cells to convert into bone cells. Within a couple of weeks, the researchers found that the cells had grown in numbers, producing high levels of bone-associated proteins, minerals and other molecules. In aggregate, these cell secretions formed a scaffold, known as an extracellular matrix, with a unique composition of biological materials needed for the growth and survival of developing bone cells.

When the scaffolds are fully developed, the researchers noted that the bone cells could be removed from the scaffold and the hydrogel-based implant can then be inserted into the site of skull injury where the surrounding, healthy bones initiate healing.Over time, the 3D printed scaffolds biodegrade, leaving behind a healed bone in the right shape.

The idea is to have the bodys own bone repair machinery participate in the repair process, Kaunas said. Our biomaterial is enriched with this regenerative extracellular matrix, providing a fertile environment to naturally trigger bone and tissue restoration.

The researchers said that the 3D-printed scaffolds provide a strong structural framework that facilitates the attachment and growth of healthy bone cells. Also, they found that developing bone cells penetrate through the synthetic material, thereby increasing the functionality of the implant.

Although our current work is focused on repairing skull bones, in the near future, we would like to expand this technology for not just craniomaxillofacial defects but also bone regeneration in cases of spinal fusions and other injuries, Kaunas said.

Other contributors to this study include Candice Sears, Eli Mondragon, Zachary Richards, Nick Sears and David Chimene from the Texas A&M Department of Biomedical Engineering; and Eoin McNeill and Carl A. Gregory from the Texas A&M Health Science Center.

This research is funded by the National Institutes of Health and the National Science Foundation.

See the rest here:
Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts - Texas A&M University Today

Posted in Stem Cell Research | Comments Off on Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts – Texas A&M University Today

30,000-cell Study Maps the Development of Sound Sensing in the Mouse Inner Ear – Technology Networks

Posted: June 2, 2020 at 9:44 pm

A team of researchers has generated a developmental map of a key sound-sensing structure in the mouse inner ear. Scientists at the National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health, and their collaborators analyzed data from 30,000 cells from mouse cochlea, the snail-shaped structure of the inner ear. The results provide insights into the genetic programs that drive the formation of cells important for detecting sounds. The study also sheds light specifically on the underlying cause of hearing loss linked to Ehlers-Danlos syndrome and Loeys-Dietz syndrome.

The study data is shared on a unique platform open to any researcher, creating an unprecedented resource that could catalyze future research on hearing loss. Led by Matthew W. Kelley, Ph.D., chief of the Section on Developmental Neuroscience at the NIDCD, the study appeared online in Nature Communications(link is external). The research team includes investigators at the University of Maryland School of Medicine, Baltimore; Decibel Therapeutics, Boston; and Kings College London.

Unlike many other types of cells in the body, the sensory cells that enable us to hear do not have the capacity to regenerate when they become damaged or diseased, said NIDCD Director Debara L. Tucci, M.D., who is also an otolaryngology-head and neck surgeon. By clarifying our understanding of how these cells are formed in the developing inner ear, this work is an important asset for scientists working on stem cell-based therapeutics that may treat or reverse some forms of inner ear hearing loss.

In mammals, the primary transducers of sound are hair cells, which are spread across a thin ribbon of tissue (the organ of Corti) that runs the length of the coiled cochlea. There are two kinds of hair cells, inner hair cells and outer hair cells, and they are structurally and functionally sustained by several types of supporting cells. During development, a pool of nearly identical progenitor cells gives rise to these different cell types, but the factors that guide the transformation of progenitors into hair cells are not fully understood.

To learn more about how the cochlea forms, Kelleys team took advantage of a method called single-cell RNA sequencing. This powerful technique enables researchers to analyze the gene activity patterns of single cells. Scientists can learn a lot about a cell from its pattern of active genes because genes encode proteins, which define a cells function. Cells gene activity patterns change during development or in response to the environment.

There are only a few thousand hair cells in the cochlea, and they are arrayed close together in a complex mosaic, an arrangement that makes the cells hard to isolate and characterize, said Kelley. Single-cell RNA sequencing has provided us with a valuable tool to track individual cells behaviors as they take their places in the intricate structure of the developing cochlea.

Building on their earlier work on 301 cells, Kelleys team set out to examine the gene activity profiles of 30,000 cells from mouse cochleae collected at four time points, beginning with the 14th day of embryonic development and ending with the seventh postnatal day. Collectively, the data represents a vast catalog of information that researchers can use to explore cochlear development and to study the genes that underlie inherited forms of hearing impairment.

Kelleys team focused on one such gene, Tgfbr1, which has been linked to two conditions associated with hearing loss, Ehlers-Danlos syndrome and Loeys-Dietz syndrome. The data showed that Tgfbr1 is active in outer hair cell precursors as early as the 14th day of embryonic development, suggesting that the gene is important for initiating the formation of these cells.

To explore Tgfbr1s role, the researchers blocked the Tgfbr1 proteins activity in cochleae from 14.5-day-old mouse embryos. When they examined the cochleae five days later, they saw fewer outer hair cells compared to the embryonic mouse cochleae that had not been treated with the Tgfbr1 blocker. This finding suggests that hearing loss in people with Tgfbr1 mutations could stem from impaired outer hair cell formation during development.

The study revealed additional insights into the early stages of cochlear development. The developmental pathways of inner and outer hair cells diverge early on; researchers observed distinct gene activity patterns at the earliest time point in the study, the 14th day of embryonic development. This suggests that the precursors from which these cells derive are not as uniform as previously believed. Additional research on cells collected at earlier stages is needed to characterize the initial steps in the formation of hair cells.

In the future, scientists may be able to use the data to steer stem cells toward the hair cell lineage, helping to produce the specialized cells they need to test cell replacement approaches for reversing some forms of hearing loss. The studys results also represent a valuable resource for research on the hearing mechanism and how it goes awry in congenital forms of hearing loss.

The authors have made their data available through the gEAR portal(link is external) (gene Expression Analysis Resource), a web-based platform for sharing, visualizing, and analyzing large multiomic datasets. The portal is maintained by Ronna Hertzano, M.D., Ph.D., and her team in the Department of Otorhinolaryngology and the Institute for Genome Sciences (IGS)(link is external) at the University of Maryland School of Medicine.

Single-cell RNA sequencing data are highly complex and typically require significant skill to access, said Hertzano. By disseminating this study data via the gEAR, we are creating an encyclopedia of the genes expressed in the developing inner ear, transforming the knowledge base of our field and making this robust information open and understandable to biologists and other researchers.

This news release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process; each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge gained through basic research.

Reference: Kolla, L., Kelly, M. C., Mann, Z. F., Anaya-Rocha, A., Ellis, K., Lemons, A., Palermo, A. T., So, K. S., Mays, J. C., Orvis, J., Burns, J. C., Hertzano, R., Driver, E. C., & Kelley, M. W. (2020). Characterization of the development of the mouse cochlear epithelium at the single cell level. Nature Communications, 11(1), 116. https://doi.org/10.1038/s41467-020-16113-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
30,000-cell Study Maps the Development of Sound Sensing in the Mouse Inner Ear - Technology Networks

Posted in Stem Cell Research | Comments Off on 30,000-cell Study Maps the Development of Sound Sensing in the Mouse Inner Ear – Technology Networks

Global Stem Cell Therapy Market 2020 Research Report Insights and Analysis, Forecast to 2026 – 3rd Watch News

Posted: June 2, 2020 at 9:44 pm

The Stem Cell Therapy market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2026.

The report mainly studies the size, recent trends and development status of the Stem Cell Therapy market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Stem Cell Therapy market.

Download PDF Sample of Stem Cell Therapy Market report @ https://www.arcognizance.com/enquiry-sample/1030514

Major Players in the global Stem Cell Therapy market include:, Holostem Terapie Avanzate, Osiris Therapeutics, NuVasive, BIOTIME, Advanced Cell Technology, Caladrius, Pharmicell, JCR Pharmaceuticals, RTI Surgical, AlloSource, MEDIPOST, Anterogen, BrainStorm Cell Therapeutics

On the basis of types, the Stem Cell Therapy market is primarily split into:, Autologous, Allogeneic

On the basis of applications, the market covers:, Musculoskeletal disorders, Wounds and injuries, Cardiovascular diseases, Surgeries, Gastrointestinal diseases, Other applications

Brief about Stem Cell Therapy Market Report with [emailprotected] https://www.arcognizance.com/report/global-stem-cell-therapy-market-report-2019-competitive-landscape-trends-and-opportunities

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2014-2026) of the following regions:, United States, Europe (Germany, UK, France, Italy, Spain, Russia, Poland), China, Japan, India , Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam), Central and South America (Brazil, Mexico, Colombia), Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria), Other Regions

Chapter 1 provides an overview of Stem Cell Therapy market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Stem Cell Therapy market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 provides a full-scale analysis of major players in Stem Cell Therapy industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 4 gives a worldwide view of Stem Cell Therapy market. It includes production, market share revenue, price, and the growth rate by type.

Chapter 5 focuses on the application of Stem Cell Therapy, by analyzing the consumption and its growth rate of each application.

Chapter 6 is about production, consumption, export, and import of Stem Cell Therapy in each region.

Chapter 7 pays attention to the production, revenue, price and gross margin of Stem Cell Therapy in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 9 introduces the industrial chain of Stem Cell Therapy. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.

Chapter 10 provides clear insights into market dynamics.

Chapter 11 prospects the whole Stem Cell Therapy market, including the global production and revenue forecast, regional forecast. It also foresees the Stem Cell Therapy market by type and application.

Chapter 12 concludes the research findings and refines all the highlights of the study.

Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report:, Historical Years: 2014-2018, Base Year: 2019, Estimated Year: 2019, Forecast Period: 2019-2026,

Some Point of Table of Content:

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Global Stem Cell Therapy Market Landscape by Player

Chapter Three: Players Profiles

Chapter Four: Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

Chapter Five: Global Stem Cell Therapy Market Analysis by Application

Chapter Six: Global Stem Cell Therapy Production, Consumption, Export, Import by Region (2014-2019)

Chapter Seven: Global Stem Cell Therapy Production, Revenue (Value) by Region (2014-2019)

Chapter Eight: Stem Cell Therapy Manufacturing Analysis

Chapter Nine: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Stem Cell Therapy Market Forecast (2019-2026)

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Appendix continued

List of tablesList of Tables and FiguresFigure Stem Cell Therapy Product PictureTable Global Stem Cell Therapy Production and CAGR (%) Comparison by TypeTable Profile of AutologousTable Profile of AllogeneicTable Stem Cell Therapy Consumption (Sales) Comparison by Application (2014-2026)Table Profile of Musculoskeletal disordersTable Profile of Wounds and injuriesTable Profile of Cardiovascular diseasesTable Profile of SurgeriesTable Profile of Gastrointestinal diseasesTable Profile of Other applicationsFigure Global Stem Cell Therapy Market Size (Value) and CAGR (%) (2014-2026)Figure United States Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Europe Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Germany Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure UK Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure France Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Italy Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Spain Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Russia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Poland Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure China Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Japan Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure India Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Southeast Asia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Malaysia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Singapore Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Philippines Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Indonesia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Thailand Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Vietnam Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Central and South America Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Brazil Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Mexico Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Colombia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Middle East and Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Saudi Arabia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure United Arab Emirates Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Turkey Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Egypt Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure South Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Nigeria Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Global Stem Cell Therapy Production Status and Outlook (2014-2026)Table Global Stem Cell Therapy Production by Player (2014-2019)Table Global Stem Cell Therapy Production Share by Player (2014-2019)Figure Global Stem Cell Therapy Production Share by Player in 2018Table Stem Cell Therapy Revenue by Player (2014-2019)Table Stem Cell Therapy Revenue Market Share by Player (2014-2019)Table Stem Cell Therapy Price by Player (2014-2019)Table Stem Cell Therapy Manufacturing Base Distribution and Sales Area by PlayerTable Stem Cell Therapy Product Type by PlayerTable Mergers & Acquisitions, Expansion PlansTable Holostem Terapie Avanzate ProfileTable Holostem Terapie Avanzate Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Osiris Therapeutics ProfileTable Osiris Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table NuVasive ProfileTable NuVasive Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BIOTIME ProfileTable BIOTIME Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Advanced Cell Technology ProfileTable Advanced Cell Technology Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Caladrius ProfileTable Caladrius Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Pharmicell ProfileTable Pharmicell Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table JCR Pharmaceuticals ProfileTable JCR Pharmaceuticals Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table RTI Surgical ProfileTable RTI Surgical Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table AlloSource ProfileTable AlloSource Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table MEDIPOST ProfileTable MEDIPOST Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Anterogen ProfileTable Anterogen Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BrainStorm Cell Therapeutics ProfileTable BrainStorm Cell Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Global Stem Cell Therapy Production by Type (2014-2019)Table Global Stem Cell Therapy Production Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Production Market Share by Type in 2018Table Global Stem Cell Therapy Revenue by Type (2014-2019)Table Global Stem Cell Therapy Revenue Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Revenue Market Share by Type in 2018Table Stem Cell Therapy Price by Type (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Autologous (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Allogeneic (2014-2019)Table Global Stem Cell Therapy Consumption by Application (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Application (2014-2019)Table Global Stem Cell Therapy Consumption of Musculoskeletal disorders (2014-2019)Table Global Stem Cell Therapy Consumption of Wounds and injuries (2014-2019)Table Global Stem Cell Therapy Consumption of Cardiovascular diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Surgeries (2014-2019)Table Global Stem Cell Therapy Consumption of Gastrointestinal diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Other applications (2014-2019)Table Global Stem Cell Therapy Consumption by Region (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Region (2014-2019)Table United States Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Europe Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table China Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Japan Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table India Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Southeast Asia Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Central and South America Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

See the original post here:
Global Stem Cell Therapy Market 2020 Research Report Insights and Analysis, Forecast to 2026 - 3rd Watch News

Posted in Stem Cell Research | Comments Off on Global Stem Cell Therapy Market 2020 Research Report Insights and Analysis, Forecast to 2026 – 3rd Watch News

Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 – WhaTech Technology and Markets News

Posted: June 2, 2020 at 9:44 pm

Mesenchymal Stem Cells Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 2027

Global Mesenchymal Stem Cells Market: Snapshot

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes.

The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Report Overview @www.transparencymarketresearch.com/mesencharket.html

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cells.

These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Mesenchymal stem cells are traditionally found in the bone marrow. However, these cells can also be separated from other tissues such as cord blood, fallopian tube, peripheral blood, and fetal liver and lung.

Mesenchymal stem cells have long thin cell bodies containing a large nucleus. MSCs have enormous capacity for renewal keeping multipotency.

Due to these virtues, mesenchymal stem cells have huge therapeutic capacity for tissue repair.

Get Brochure of the Report @www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells can differentiate into a number of cell types that belong to our skeletal tissues that include cartilage, bone, and fat. Research is underway to discover if mesenchymal stem cells can be used to treat bone and cartilage diseases.

Scientists are also exploring the possibility if mesenchymal stem cells differentiate into other type of cells apart from skeletal tissues. This includes nerve cells, liver cells, heart muscle cells, and endothelial cells.

This will lead to mesenchymal stem cells to be used to treat other diseases.

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue.

Request For Covid19 Impact Analysis http://www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation.

These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area.

The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses.

Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases.

Pre Book Now @www.transparencymarketresearch.com/checkoump;ltype=S

Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex.

In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues.

Traditionally the MSCs were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSCs from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing.

In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Read our Case study at :www.transparencymarketresearch.com/casestug-start-up

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives.

Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read the original:
Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News

Posted in Stem Cell Research | Comments Off on Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 – WhaTech Technology and Markets News

AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other…

Posted: June 2, 2020 at 9:44 pm

ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Imstem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeXs embryonic stem cell line ESI 053 to derive ImStems investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes. AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement.

ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001 product which is being investigated for multiple sclerosis under an IND. Earlier this year, the U.S. Food and Drug Administration (FDA) cleared IMS001 to begin a Phase 1 clinical study in patients with multiple sclerosis, after a clinical hold on its Investigational New Drug (IND) application was removed. This is believed to be the first MSC product derived from human embryonic stem cells to be accepted for a clinical trial by the FDA. AgeX and ImStem already have a commercial license in place, which grants ImStem rights to use AgeXs ESI 053 to derive IMS001 as a product candidate for development in autoimmune disease, including multiple sclerosis.

To date, in patients with pneumonia and ARDS due to COVID-19, preliminary literature suggests MSCs, such as ImStems hES-MSC candidate IMS001, may warrant further development consideration. An early clinical study conducted in China by an unrelated group with a different MSC product, Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia, and published in Aging and Disease (2020, Vol. 11, No. 2, pp. 216-228) showed that an intravenous infusion of a different MSC product appeared safe and improved functional outcomes in seven treated patients with COVID-19 pneumonia. MSCs are well recognized to be immunomodulatory in nature, possessing immunosuppressive and anti-inflammatory properties.

Even before their application to COVID-19, MSCs were being investigated as a potential therapeutic option in ARDS, and emerging data in preclinical models has been encouraging. ARDS remains an area of considerable unmet medical need, affecting around 200,000 patients annually in the U.S., accounting for 10% of all intensive care unit patients, and having a mortality of approximately 40%. At the present time, no specific direct therapies exist for ARDS and only supportive treatment is available.

We feel privileged to be part of a global effort to combat COVID-19. This is a unique opportunity for AgeX to leverage its resources to help with the public health challenge at hand. Decades of pioneering work with human embryonic stem cells means this technology is now at a point where it may play a role in the development of a cell-based approach to combating COVID-19. We are very excited by the prospect of expanding our relationship with ImStem to include COVID-19 and ARDS, said Dr. Nafees Malik, Chief Operating Officer of AgeX.

We welcome the opportunity to continue to collaborate with AgeX and explore future development of our IMS001 product in COVID-19 and ARDS from other causes, commented Richard Kim, M.D., Chief Medical Officer of ImStem Biotechnology.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

About ImStem Biotechnology

ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The company's mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology Inc. is a privately held company headquartered in Farmington, CT.

For more information, visit http://www.imstem.com.

Forward-Looking Statements for AgeX

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs letter of intent with ImStem there is no assurance that (i) AgeX and ImStem will successfully conclude negotiations and enter into a license agreement; (ii) ImStem will be successful in developing any therapeutic products from a stem cell line licensed by AgeX or that any therapeutic product that may be developed will receive FDA or foreign regulatory approval, or (iii) AgeX will derive revenue or other financial benefits from any license agreement that might be signed with ImStem. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005353/en/

See the rest here:
AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other...

Posted in Stem Cell Research | Comments Off on AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other…

Page 999«..1020..9989991,0001,001..1,0101,020..»